Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its popular obesity and diabetes injections.

Novo Nordisk launches its first GLP-1 product, liraglutide, branded as Victoza in 2009 in Europe and in 2010 in the U.S. In 2013, Novo Nordisk's semaglutide starts global phase 3 trials.

At the time, the NYT noted that no other company had bid on the contract, which covered supply of 14 million pens for three years at roughly $2 per device. Novo had been supplying insulin pens to ...

Novo Nordisk (NVO) reportedly plans to phase out production of its human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. The Danish drugmaker ...

The nonprofit published a paper on insulin pen prices in March, in which it said the devices cost $1.99 in South Africa, $5.77 in India and $14.00 in the Philippines.

MSF estimates insulin pens can be produced for $0.94 while being profitable; current U.S. price is $90.69. Diabetes affects 537 million globally, with African cases expected to rise by 134% by ...

Novo launched the NovoPen - the first insulin pen device in 1985. 2000–2017 Lars Rebien Sorensen becomes CEO after serving as the head of Novo's healthcare business.